Vivos Therapeutics Inc
NASDAQ:VVOS
Vivos Therapeutics Inc
NASDAQ:VVOS
Price:
2.07 USD
-1.43%
Market Closed
Updated:
May 29, 2024
Vivos Therapeutics Inc
Cash & Cash Equivalents
|
Vivos Therapeutics Inc
Cash & Cash Equivalents Peer Comparison
Comparables:
DVA
DGX
CVS
CI
LH
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
Cash & Cash Equivalents
$1.6m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
Cash & Cash Equivalents
$345.1m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash & Cash Equivalents
$474m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
13%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cash & Cash Equivalents
$9.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
|
Cigna Corp
NYSE:CI
|
Cash & Cash Equivalents
$8.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash & Cash Equivalents
$99.3m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-12%
|
See Also
What is Vivos Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.6m
USD
1.6m
USD
Based on the financial report for Dec 31, 2023, Vivos Therapeutics Inc's Cash & Cash Equivalents amounts to 1.6m USD.
What is Vivos Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
6%
6%
Over the last year, the Cash & Cash Equivalents growth was -53%. The average annual Cash & Cash Equivalents growth rates for Vivos Therapeutics Inc have been -55% over the past three years , 6% over the past five years .
You don't have any saved screeners yet
